EE153 Budget Impact Analysis of Introducing Mobocertinib for Locally Advanced or Metastatic Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small-Cell Lung Cancer in the United States from the Payer Perspective
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.402
https://www.valueinhealthjournal.com/article/S1098-3015(22)00603-9/fulltext
Title :
EE153 Budget Impact Analysis of Introducing Mobocertinib for Locally Advanced or Metastatic Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small-Cell Lung Cancer in the United States from the Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00603-9&doi=10.1016/j.jval.2022.04.402
First page :
Section Title :
Open access? :
No
Section Order :
10353